Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies

Icotinib is a new epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that developed and used in China; this work was to evaluate its efficacy and safety in treating non-small cell lung cancer (NSCLC). Clinical studies evaluating the efficacy and safety of icotinib in treating NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Biaoxue, Rong, Hua, Liu, Wenlong, Gao, Shuanying, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349962/
https://www.ncbi.nlm.nih.gov/pubmed/27893423
http://dx.doi.org/10.18632/oncotarget.13509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349962/
https://www.ncbi.nlm.nih.gov/pubmed/27893423
http://dx.doi.org/10.18632/oncotarget.13509

Ejemplares similares